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Abstract
Objectives: The use of assistive technology and telecare (ATT) has been promoted to manage risks associated with independent
living in people with dementia but with little evidence for effectiveness.
Methods: Participants were randomly assigned to receive an ATT assessment followed by installation of all appropriate ATT
devices or limited control of appropriate ATT. The primary outcomes were time to institutionalisation and cost-effectiveness.
Key secondary outcomes were number of incidents involving risks to safety, burden and stress in family caregivers and quality
of life.
Results: Participants were assigned to receive full ATT (248 participants) or the limited control (247 participants). After
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95% CI, 0.63 to 1.12; P = 0.20. There were no significant differences between arms in health and social care (mean -£909;
95% CI, -£5,336 to £3,345, P = 0.678) and societal costs (mean -£3,545; 95% CI, -£13,914 to £6,581, P = 0.499). ATT
group members had reduced participant-rated quality-adjusted life years (QALYs) at 104 weeks (mean − 0.105; 95% CI,
−0.204 to −0.007, P = 0.037) but did not differ in QALYs derived from proxy-reported EQ-5D.
Discussion: Fidelity of the intervention was low in terms of matching ATT assessment, recommendations and installation.
This, however, reflects current practice within adult social care in England.
Conclusions: Time living independently outside a care home was not significantly longer in participants who received full
ATT and ATT was not cost-effective. Participants with full ATT attained fewer QALYs based on participant-reported EQ-5D
than controls at 104 weeks.
Keywords: assistive technology, telecare, dementia, social care, independent living, older people
Key Points
• There have been no large clinical trials of the clinical and cost-effectiveness and safety of assistive technology and telecare
(ATT).
• In this randomised clinical trial (RCT) of 495 people comparing those with ATT to the control, the adjusted hazard ratio
was 0.84, which was not significant.
• The study suggests that ATT does not enable people with dementia to maintain safe independent living for longer in their
homes.
Introduction
Dementia represents a major and growing challenge for
patients, their families, health and social care systems and
society as a whole. In 2016, the global number of dementia
cases was 43.8 million [1] and annual global costs of demen-
tia (mostly from informal and social care) could grow to $2
trillion by 2030 [2]. Dementia is also the most common
single reason for care home entry [3], as progression of
cognitive and functional impairment and the expression of
risky behaviours undermine ability to live independently
with safety. Quality of life for people with dementia worsens
following care home placement [4]. Maximising the time
people with dementia can spend in their own homes repre-
sents the most economically efficient long-term care model
[5] and has become the stated policy in many care systems,
including in the UK [6].
Assistive technology (AT) refers to electronic or mechan-
ical devices that can support independence and improve
quality of life by assisting with daily living activities, reducing
harmful risks and improving communication. Devices used
in dementia care can be broadly categorised as reminder
or prompting devices, monitors and detectors to support
safety, safer walking technologies, communication devices
and devices to support use of leisure activities [7]. Telecare
uses a combination of monitored alarms, sensors and other
equipment to help people live independently [8]. Largely on
the basis of data from uncontrolled project evaluations [9],
assistive technology and telecare (ATT) has been promoted
to support people with dementia to live independently [8].
The Whole Systems Demonstrator included a large ran-
domised clinical trial (RCT) of telecare in the UK and found
no overall reduction in people having to move into care
homes, although people with dementia were not specifically
recruited to the trial [10]. Meta-analysis of two small and
short randomised controlled trials in people with dementia
found no significant delay of care home entry with ATT [11].
We carried out a pragmatic RCT, Assistive Technology
and Telecare to maintain Independent Living At home in
people with dementia (ATTILA trial), to test the clinical
and cost-effectiveness of ATT in supporting people with
dementia to continue to live safely within their own homes.
Methods
Patients and procedures
Participants were people diagnosed with dementia or cog-
nitive difficulties sufficient to suggest dementia, who met
English Social Services’ eligibility criteria for Fair Access
to Care Services and were consequently entitled to receive
services [12], were living in the community (including shel-
tered/supported and very sheltered/supported accommoda-
tion) within 11 local authority areas in England, and had
a working telephone line. Exclusion criteria were: current
receipt of an ATT intervention, previous unsuccessful instal-
lation of ATT and an identified urgent need for a home
care package. Informed written consent was obtained from
participants and from caregivers who provided data.
Trial design
The trial compared outcomes in participants randomised,
on a one-to-one allocation, to receive: (1) an ATT needs
assessment, followed by installation of indicated ATT devices
and response services (ATT Intervention), or (2) ATT needs
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and carbon monoxide detectors and a pendant alarm, if
indicated (ATT Control) Table 1. Co-primary outcomes
were time to residential care entry and cost-effectiveness [13].
Secondary outcome measures included burden and quality
of life in unpaid carers, the number and severity of serious
adverse events and data on acceptability, applicability and
reliability of ATT packages.
The study was approved by the UK National Health
Service Health Research Authority National Research Ethics
Committee (Reference 12/LO/186) and was registered
(ISRCTN86537017).
Trial end-points and assessments
Time in days from randomisation to institutionalisation was
defined as time to permanent transition from living in
participant’s own home to a nursing or residential care
home or admission to an acute care facility that resulted
in permanent move into a residential care or nursing
home. Cost-effectiveness: We examined the incremental
cost of community-based support: per institutional day
avoided (days to institutionalisation), per quality-adjusted
life year (QALY) lived in the community and per minimum
clinically important difference (of 0.074) in the EQ-5D
index [14]. EQ-5D index scores (utilities) were available
from both participant and caregivers. Analyses took a
health and social care perspective and a societal perspective
(costs to participant and caregiver, including out-of-pocket
payments for home adaptations, ADL equipment, travel to
appointments and opportunity costs of providing unpaid
care).
Secondary trial outcome assessments included the Bristol
Activities of Daily Living Scale (BADLS) [15], Standard-
ised Mini-Mental State Examination (SMMSE) [16] and
Model of Human Occupation Screening Tool (MOHOST)
[17] at baseline. Additional outcome measures were partici-
pant’s quality of life measured with the EuroQol EQ-5D-5L
[14] and unpaid caregiver outcome measures including the
Zarit Burden Inventory [18], the Centre for Epidemiological
Studies Depression Scale [19], the State Trait Anxiety Inven-
tory [20], the Short Form Health Survey [21] and the Carer
Technology Acceptance Questionnaire [22].
Statistical analyses
Analyses were by intention to treat, with all randomised par-
ticipants included in the comparison and analysed according
to their randomised allocation, including those who discon-
tinued the trial. Time to institutionalisation was compared
between intervention and control arms using survival anal-
ysis methods. Kaplan–Meier survival curves were created
for graphical representation of the time to event compar-
isons. Statistical significance was determined by the log
rank test. Analyses included all events, even those occurring
after 2 years. Participants who died, withdrew from follow-
up or were lost to follow-up were censored at the date of
withdrawal from the study. Continuous outcome measures
were analysed using repeated measures regression techniques
to maximise statistical power.
Costs and cost-effectiveness analyses
Costs were calculated on the basis of caregiver-reported
service use over the prior 3 months at baseline, 12, 24,
52 and 104 weeks, attaching nationally applicable unit cost
measures to health and social care use for each participant
using the Client Service Receipt Inventory (CSRI) [23]. The
costs of the intervention were calculated drawing on infor-
mation from key informant interviews, nationally appli-
cable unit costs and price information from procurement
frameworks provided by the Northern Housing Consortium
[24]. Costs and days in the community were discounted
at 3.5% annually [25]. Mixed effects linear difference-in-
difference models compared the between-group difference
in EQ-5D scores [26, 27] and average 3-month costs over
the follow-up relative to baseline. Analyses of days lived in
the community, QALY, total health and social care costs
and total societal costs combined group-level estimates from
different models (gamma generalised linear model with a
square root link for costs, with inverse-probability weights
derived from parametric models, [28, 29, 30] Weibull accel-
erated failure time model for days in the community, group-
mean utilities to calculate QALY by the integrated quality
survival product method) [30,31]. Bootstrap standard errors
of the estimates of costs, QALY and days in the community
(based on 25,000 replications) and of costs and the EQ-5D
index (based on 5,000 replications were produced). Cost-
effectiveness acceptability curves (CEACs) were constructed
from bootstrapped estimates to depict the probability of
cost-effectiveness at a series of threshold willingness to pay
for an incremental effect, ranging from £0 to £50,000.
This range included the National Institute for Health and
Care Excellence (NICE) threshold of between £20,000 and
£30,000 per QALY.
Sample size estimations were based on the observation that
50% of participants with a BADLS score of >15 would be
expected to have entered residential care after 24 months
[32], so that a 30% reduction in the institutionalisation
rate from 50% to 35% would require involvement of 500
participants, allowing for 10% attrition due to death whilst
still community resident. This would equate to an average
of 55 days of longer independent home life for participants
receiving the intervention.
Patient and public involvement
The study was supported by Alzheimer’s Society Research
Network volunteers, who were past or current family care-
givers of a person with dementia, and who partnered with
us in the study design, the wording of information materials
and consent documentation and were members of the Trial
Steering Group. At the end of the trial they commented on
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Table 1. ATT installations 12–104 weeks (for intervention arm only)
12 weeks 24 weeks 52 weeks 104 weeks Total (12–104 weeks)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intervention technology installed
Reminder/Prompting 116/580 (20%) 18/124 (15%) 9/87 (10%) 17/97 (18%) 160/888 (18%)
Safety 220/580 (38%) 45/124 (36%) 30/87 (35%) 43/97 (44%) 338/888 (38%)
Communication 8/580 (1%) 1/124 (0%) 2/87 (2%) 1/97 (1%) 12/888 (2%)
Support leisure time 1/580 (0%) 2/124 (2%) 1/87 (1%) 0/97 (0%) 4/888 (0%)
Any other devices 0/580 (0%) 0/124 (0%) 0/87 (0%) 0/97 (0%) 0/888 (0%)
Total installed 580 124 87 97 888
Total installed 580 124 87 97 888
Table 2. Baseline characteristics
Intervention N = 248 Control N = 247
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age <65 11 (4%) 4 (2%)
65–80 89 (36%) 93 (38%)
80+ 148 (60%) 150 (61%)
Age Mean (SD) 81.0 (8.2) 80.8 (7.4)
Gender Male 102 (41%) 103 (42%)
Female 146 (59%) 144 (58%)
Risk of wandering/leaving home
inappropriately
Low 178 (72%) 180 (73%)
Medium 52 (21%) 48 (19%)
High 18 (7%) 19 (8%)
Safety risks within home identified Low 125 (50%) 124 (50%)
Medium 104 (42%) 101 (41%)
High 19 (8%) 22 (9%)
Level of caregiver support Live in 119 (48%) 121 (49%)
Once daily 60 (24%) 61 (25%)
Less than once daily 69 (28%) 65 (26%)
SMMSE Score∗ 0–9 23 (10%) 34 (15%)
10–19 79 (36%) 96 (43%)
20–25 87 (39%) 74 (33%)
26–30 32 (14%) 19 (9%)
SMMSE Score Mean (SD) 18.7 (6.6) 16.9 (6.9)
BADLS Score∗∗ 0–4 17 (7%) 10 (4%)
5–14 72 (31%) 64 (28%)
15–29 95 (41%) 102 (45%)
30+ 46 (20%) 49 (22%)
BADLS Score Mean (SD) 19.5 (11.3) 20.4 (10.9)
∗51 participants did not have a baseline SMMSE Score. ∗∗40 participants did not have a baseline BADLS Score.
Results
Between 14 August 2013 and 26 October 2016, 495 par-
ticipants were randomised from 11 recruiting sites (listed
in online supplement) in England. Outcomes of Baseline
structured ATT needs assessments and details of the indi-
vidual ATT components that were installed in participants’
homes have been previously reported [33]. Appendix A1 is
the Consort diagram of the flow of participants through the
trial. During follow-up, 200 participants were admitted to
care, 89 died, 42 withdrew from follow-up and 18 were lost
to follow-up. Once a participant had entered residential care,
no further outcome assessments took place.
Participant baseline demographic characteristics were bal-
anced across arms (Table 2). Participants in the ATT inter-
vention arm, however, had higher mean sMMSE scores (18.7
versus 16.9) and lower BADLS scores (19.5 versus 20.4). A
lower BADLS score indicates less impairment of activities of
daily living.
Time to entering care
Comparing ATT to control, the unadjusted hazard ratio
(HR) was 0.75 (95% confidence interval (CI) 0.58 to 1.01;
P = 0.054) (Figure 1A). Rates of entry to care, however, were
significantly affected by participants’ baseline BADLS scores.
Participants with a higher baseline BADLS score (indicating
greater impairment of activities of daily living) were more
likely to be admitted to care (P < 0.0001) (Appendix A2),
and there were more participants in the intervention group
with a lower baseline score (Table 2). Figure 1B is a forest
plot of time to admission to care between intervention
groups, split by baseline BADLS scores. When we adjusted
for baseline BADLS score, there was no significant difference
in time to entry to care (HR 0.84 (95% CI 0.63 to 1.12,
P = 0.20)).
To determine whether ATT might have helped prevent
individual entries to care, the reasons for institutionalisation
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Figure 1. (A) Kaplan–Meier survival curve of time to admission to care by randomised intervention unstratified. (B) Forest plot of
time to admission to care by randomised intervention adjusted for baseline BADLS score.
reason for entering care was inability to perform activities
of daily living, and this was reduced in the intervention
group (14 versus 29; P = 0.016). Moving to a care home
because of safety concerns, which might have been expected
to be reduced by ATT, was actually more common in the
intervention group (12 versus 4, P = 0.043). Wandering,
a behaviour whose associated risks might be mitigated by
appropriate ATT, was non-significantly reduced as a reason
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Costs
Appendix A4 shows the flow of dyads participating in full
cost assessments. Appendix A5 contains descriptive demo-
graphics for the sample participating in full baseline cost
assessments. Appendices A6 and A7 present service use and
costs at each assessment point. Participants were high users of
health and social care services. Use and costs increased during
follow-up (Appendices A6 and A7). Cumulative costs of the
intervention and total health, social care and societal costs
are presented in Appendix A8. ATT costs over the follow-up
were modest (Intervention: £322 (SE £18); Control: £214
(SE £16)).
Health-related quality of life
Raw mean participant-rated EQ-5D index scores were lower
in the intervention than the control group at 52 (mean
difference − 0.079, 95% CI -0.139 to −0.018, P = 0.011)
and 104 weeks (mean difference − 0.088, 95% CI -0.169 to
−0.008, P = 0.032) (Appendix A9).
Cost-effectiveness
Based on participant-rated EQ-5D (Appendix A10), indi-
viduals in the intervention arm had significantly lower QALY
at weeks 52 (mean difference − 0.044 (95% CI -0.088 to
0.000, P = 0.05)) and 104 (mean difference − 0.105 (95%
CI -0.204 to −0.007, P = 0.037)). Allocation groups did not
differ significantly in QALYs derived from proxy-reported
EQ-5D at any point. There were no significant differences
in 24-week, 52-week and 104-week censor-adjusted health
and social care and societal costs between intervention and
control participants (Appendix A10). Change in EQ-5D-
participant and EQ-5D-proxy index scores did not differ
between groups at 24, 52 or 104-weeks, nor did change in
follow-up costs from baseline (Appendices A10–A16).
Point incremental cost-effectiveness ratios (ICERs) for
institutionalisation-free days and for proxy-reported QALY
at 104 weeks were negative. The 104-week ICER for
participant-reported QALY was positive because, while costs
were non-significantly lower in the intervention group,
QALY were significantly lower in the intervention group.
Point ICER for a minimal clinically important difference
(MCID) of 0.074 [34,35] in participant-reported EQ-5D at
104 weeks was negative from either perspective because the
outcome was (non-significantly) worse in the intervention
group, with small positive differences in costs. Point ICER
for an MCID in proxy-reported EQ-5D at 104 weeks was
positive (small positive differences in outcomes and costs)
from the health and social care services perspective, but
negative (small positive differences in outcomes and small
negative differences in costs) from the societal perspective.
CEACs for each outcome, where the point ICER was not
the result of a worse outcome for the intervention group, are
shown in Appendices A17–A19. CEACs for change in the
EQ-5D-proxy (24, 52 and 104 weeks), QALYs derived from
the EQ-5D-proxy (24, 52 and 104 weeks), and for days in
the community (104 weeks) reflect the sampling uncertainty
in the cost and outcomes analyses and indicate that we
cannot be confident at the 95% level that the ATTILA
intervention was cost-effective.
Sensitivity analysis of the cost of unpaid care: valuing
unpaid caregivers’ time at replacement cost, more than
doubled societal costs in both groups (Appendix A20),
but ICERs were in line with the results of the main
cost-effectiveness analyses (Appendix A21).
Serious adverse events
A total of 89 participants died whilst community resident,
41 in the intervention arm and 48 in the control arm
(Appendices A22 and A23). There were no significant differ-
ences seen overall (P = 0.14 Appendix A21) or in the grouped
categories for causes of death (Appendix A23).
Serious adverse events (SAEs) were categorised and the
number of participants reporting SAEs are summarised in
Table 3. Appendix A24 plots the number of participants
experiencing each SAE type with a test of significance for dif-
ferences between intervention and control arms. There was a
significant reduction in participants experiencing behaviour-
related SAEs in the intervention group when compared to
the control group (P = 0.01). More participants experienced
SAEs related to safety concerns in the intervention group
than in the control group (P = 0.06).
Discussion
ATTILA is the first randomised controlled trial of ATT in
people with dementia, which was powered to detect mod-
erate benefits associated with the use of the technology. We
found provision of home-based technology, installed follow-
ing an individual needs assessment within current practice
in England, had no significant effect on the time that people
with dementia were able to continue to live independently in
their own homes. There was no evidence of cost-effectiveness
in terms of days lived in the community, impact on health-
related quality of life or QALY based on proxy-reported EQ-
5D, from the health and social care or societal perspective.
The ATT intervention group attained fewer QALY, based
on participant-reported EQ-5D over 104 weeks, than the
control group.
Optimising the care of people with dementia within their
own homes, to delay or reduce transition to alternative
care settings, is preferred by people with dementia; this
maintains higher quality of life [4, 36], costs less [37] and
is a public health imperative [5]. A major role for ATT and
robotics in augmenting human care provision in the homes
of people with dementia is anticipated [38], yet there are very
little available data on the effectiveness, safety and costs of
the technology [39]. Currently available technologies have
focussed on monitoring well-being, safety, physical activity
and social participation, but robotic devices to assist with
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Table 3. SAEs categorised, P-value from Mantel–Haenszel test (ignoring time to event)
Categorised SAE Intervention, no. of
participants
Control, no. of participants Total no. of participants P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Safety concerns 13 5 18 0.06
Wandering 25 36 61 0.13
Falls 86 88 174 0.83
Dementia progression 37 43 80 0.45
Behaviour 5 16 21 0.01
Other medical condition 107 109 216 0.83
Carer related 11 10 21 0.83
Environmental/accident 13 15 28 0.69
Health deterioration 5 2 7 0.26
Other 2 1 3 0.57
Unknown 10 16 26 0.22
Total no. of participants 195 201 396 0.45
technologies to improve social participation are also being
actively marketed [38].
ATTILA aimed to answer a simple but important ques-
tion: would the provision of a full package of ATT increase
the length of time that people with dementia were able to
live safely and independently in their own homes, com-
pared to provision of a very basic package? Whilst the
results indicate that a full ATT package did not extend the
time lived in the community, the planned survival analyses
could not control for all the factors that might underlie
the difficult decision to enter residential care. When the
reasons for moving into care were compared between trial
arms (Appendix A3), participants allocated to the full ATT
package were less likely to move because of wandering or
loss of activities of daily living function, but more likely to
move because of concerns about safety at home. Although
the number of participants moving for each of these reasons
was small within the overall trial, differences between trial
arms provide evidence that ATT may be able to reduce the
risks associated with some of the common reasons for a move
to care in a small number of people. It is also possible that
the provision of a full ATT package leads to an increased
awareness of safety concerns with consequent shortening of
independent living. This could also underlie reductions in
QALY based on participants’ own ratings in the intervention
group. Qualitative work, undertaken as part of the study,
found that people with dementia and their caregivers some-
times experienced the technology as disruptive to their daily
lives.
Rates of admission to care in people with Alzheimer’s
disease are influenced by functional ability. In our analyses,
we found a highly significant effect of Baseline BADLS score
on time to admission to care. Participants with a higher
Baseline BADLS (indicating more impairment of function)
were more likely to be admitted to care (P < 0.0001). Unfor-
tunately and by chance, there was an imbalance in Baseline
BADLS scores between participants in the intervention and
control arms. More participants in the intervention arm
had lower BADLS scores (indicating less impairment of
function). Consequently, we adjusted for this difference at
Baseline in the primary analysis.
ATT installation to meet imposed performance targets
can reduce accurate matching of technology to need, [40]
and the assessor’s understanding of technology and need
can be suboptimal [41]. We have reported elsewhere the
outcomes of the ATTILA standardised needs assessments in
terms of the ATT components that were recommended for
participants, and that there was limited fidelity of technology
recommendation to the ATTILA needs assessment [33]. This
finding is a potential major limitation and the trial’s negative
results need to be viewed in this light. ATTILA was, however,
a large and pragmatic trial, which examined the effectiveness
of ATT in a real-world setting within which technology is
currently deployed to support people with dementia living
in their own homes. Our results are likely to be generalisable
to real world settings within which ATT is used.
We recognise several limitations to generalisability of
results from this study. Blinding to allocation of participants
and assessors was not undertaken as this would not have
been feasible and would have been a potential source of bias.
Although we obtained data from caregivers, recall bias could
have affected the precision and size of cost estimates. Estima-
tion of costs in intervals not covered by the cost collection
instrument assumed constant use of most services between
intervals (although ED and hospital admission costs reflected
use during those intervals). Participant-reported EQ-5D
ratings were missing in substantial numbers at follow-up.
The analyses of QALY drew on group mean utilities at each
time point and did not adjust for baseline characteristics. The
finding that the ATT intervention group had lower QALYs
on the participant-reported EQ-5D-5L must be interpreted
with caution, given the substantial rates of attrition on that
measure.
Our data suggest that it would be premature to conclude
that more extensive ATT systems to support independent
home living for people with dementia are clinically impor-
tant or cost-effective compared to more basic systems. This
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pendant alarms are themselves effective in preventing harms,
or because more extensive ATT systems are inadequately
supported by providers, or inadequately tailored to the needs
of people with dementia and their caregivers [33].
Supplementary data: Supplementary data mentioned in
the text are available to subscribers in Age and Ageing online.
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